Susquehanna International Group
RVNC

Susquehanna International Group’s Revance Therapeutics, Inc. RVNC Stock Holding History

Susquehanna International Group’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-303,073
Closed -$921K – 13773
2024
Q4 		$921K Buy
303,073
+246,442
+435% +$1.07M ﹤0.01% 7166
2024
Q3 		$294K Sell
56,631
-120,342
-68% -$598K ﹤0.01% 9647
2024
Q2 		$455K Buy
176,973
+57,064
+48% +$195K ﹤0.01% 8484
2024
Q1 		$590K Buy
119,909
+87,783
+273% +$520K ﹤0.01% 8105
2023
Q4 		$282K Sell
32,126
-104,541
-76% -$857K ﹤0.01% 9955
2023
Q3 		$1.57M Sell
136,667
-3,071
-2% -$59K ﹤0.01% 5634
2023
Q2 		$3.54M Buy
139,738
+86,073
+160% +$2.68M ﹤0.01% 4089
2023
Q1 		$1.73M Sell
53,665
-207,453
-79% -$6.47M ﹤0.01% 5462
2022
Q4 		$4.82M Buy
261,118
+163,037
+166% +$3.73M ﹤0.01% 3295
2022
Q3 		$2.65M Sell
98,081
-36,963
-27% -$750K ﹤0.01% 4339
2022
Q2 		$1.87M Sell
135,044
-12,393
-8% -$191K ﹤0.01% 5064
2022
Q1 		$2.88M Buy
147,437
+100,134
+212% +$1.52M ﹤0.01% 4705
2021
Q4 		$772K Sell
47,303
-3,385
-7% -$56.4K ﹤0.01% 7975
2021
Q3 		$1.41M Sell
50,688
-10,219
-17% -$292K ﹤0.01% 6648
2021
Q2 		$1.8M Buy
60,907
+12,039
+25% +$347K ﹤0.01% 6152
2021
Q1 		$1.37M Sell
48,868
-95,195
-66% -$2.63M ﹤0.01% 6917
2020
Q4 		$4.08M Buy
144,063
+117,736
+447% +$3.05M ﹤0.01% 3768
2020
Q3 		$662K Sell
26,327
-4,057
-13% -$106K ﹤0.01% 7085
2020
Q2 		$742K Sell
30,384
-85,097
-74% -$1.68M ﹤0.01% 6545
2020
Q1 		$1.71M Buy
115,481
+39,949
+53% +$826K ﹤0.01% 4253
2019
Q4 		$1.23M Sell
75,532
-19,864
-21% -$308K ﹤0.01% 5130
2019
Q3 		$1.24M Buy
95,396
+29,735
+45% +$364K ﹤0.01% 5231
2019
Q2 		$852K Buy
+65,661
New +$828K ﹤0.01% 6050
2018
Q4 		– Sell
-14,158
Closed -$312K – 10152
2018
Q3 		$352K Buy
+14,158
New +$385K ﹤0.01% 7162
2018
Q1 		– Sell
-180,105
Closed -$5.79M – 10351
2017
Q4 		$6.44M Buy
180,105
+106,243
+144% +$3.05M ﹤0.01% 2257
2017
Q3 		$2.04M Buy
+73,862
New +$1.79M ﹤0.01% 3873
2017
Q1 		– Sell
-31,714
Closed -$651K – 10172
2016
Q4 		$656K Buy
+31,714
New +$531K ﹤0.01% 6416
2016
Q2 		– Sell
-39,781
Closed -$703K – 9474
2016
Q1 		$695K Sell
39,781
-31,032
-44% -$632K ﹤0.01% 5813
2015
Q4 		$2.42M Buy
70,813
+36,224
+105% +$1.26M ﹤0.01% 3668
2015
Q3 		$1.03M Buy
34,589
+5,505
+19% +$167K ﹤0.01% 5690
2015
Q2 		$930K Buy
+29,084
New +$748K ﹤0.01% 6372
2014
Q3 		– Sell
-10,331
Closed -$351K – 10037
2014
Q2 		$351K Buy
+10,331
New +$324K ﹤0.01% 8112

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Susquehanna International Group's RVNC Position: Q1 2025 in Review

Susquehanna International Group sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 303,073 shares — an estimated $921K sold.

Susquehanna International Group first reported a position in RVNC in Q2 2014 and held it in 32 quarters. The position peaked at $6.44M in Q4 2017. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Susquehanna International Group reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Susquehanna International Group sold 303,073 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $921K.
  • Susquehanna International Group first reported a position in Revance Therapeutics, Inc. in Q2 2014 and held it in 32 quarters.
  • Susquehanna International Group's Revance Therapeutics, Inc. position peaked at $6.44M in Q4 2017.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.